Protocol #: 17-231
Status
Recruiting
Description
This research study is studying a drug in combination with radiation therapy as a possible treatment for hepatic metastases from colorectal cancer. The interventions involved in this study are: - Trifluridine (TAS-102) - Radiation Therapy
Condition
Colorectal Cancer
Interventions
TAS-102
Photon SBRT
Phase
Phase 1/Phase 2
Study Type
Interventional
Further Study Details
Primary Outcome:
Maximum Tolerated Dose (MTD)
The Duration of Local Control
Secondary Outcome:
Toxicity associated with TAS-102 combined with SBRT
Progression Free Survival
Overall Survival
Association between KRAS or BRAF mutation status with local control
Serial ctDNA
Estimated Enrollment
56
Study Start Date
October 13, 2017
Eligibility
Gender: All
Minimum Age: 18 Years
Maximum Age: N/A
Health Volunteers: No
Criteria
Massachusetts General Hospital
Information Provided By
Massachusetts General Hospital
Official Title
Phase Ib/II Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer
Clinicaltrials.gov Identifier
NCT03223779

 

 

Source: Clinicaltrials.gov. Through our founding membership in the Dana-Farber/Harvard Cancer Center, an NCI-designated Comprehensive Cancer Center, these clinical trials are conducted at the Massachusetts General Hospital Cancer Center and may be available at other partner institutions.

Back to Top